Revenue has contracted to $2.1M in 2026Q2 from $6.8M in 2024Q2 (~69% decline) on lumpy milestone recognition that swung gross margin between -124.6% (2026Q1) and 100% (2026Q2), while R&D and SG&A cuts of ~30% and ~72% respectively narrowed operating losses to -$31.1M.
Fate Therapeutics, Inc. (FATE) annual income statement — 15-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Sales/Revenue | 4.75M | 6.65M | 13.63M | 63.53M | 96.3M | 55.85M | 31.43M | 10.68M | 4.74M | 4.11M | 4.4M | 2.43M | 0 | 971K | 2.67M | 1.17M |
| Revenue Growth % | -33.45% | -51.24% | -78.55% | -34.03% | 72.44% | 77.66% | 194.33% | 125.32% | 15.44% | -6.72% | 81.08% | - | -100% | -63.63% | 128.21% | - |
| Cost of Goods Sold | 5.6M | 12.9M | 118.53M | 157.19M | 13.76M | 5.85M | 125.62M | 0 | 56.02M | 34.36M | 26.45M | 19.86M | 16.43M | 12.01M | 12M | 0 |
| COGS % of Revenue | - | 194.12% | 869.57% | 247.41% | 14.29% | 10.48% | 399.64% | - | 1181.94% | 836.78% | 600.91% | 816.99% | - | 1236.56% | 449.4% | - |
| Gross Profit | -846K | -6.25M | -104.9M | -93.65M | 82.54M | 50M | -94.19M | 10.68M | -51.28M | -30.25M | -22.05M | -17.43M | -16.43M | -11.04M | -9.33M | 1.17M |
| Gross Margin % | -17.81% | -94.12% | -769.57% | -147.41% | 85.71% | 89.52% | -299.64% | 100% | -1081.94% | -736.78% | -500.91% | -716.99% | - | -1136.56% | -349.4% | 100% |
| Gross Profit Growth % | - | 94.04% | -12.01% | -213.46% | 65.1% | 153.08% | -981.92% | 120.83% | -69.52% | -37.2% | -26.51% | -6.05% | -48.92% | -18.3% | -897.35% | - |
| Operating Expenses | 130.26M | 141.45M | 105.38M | 96.86M | 390.93M | 266.99M | 33.9M | 111.41M | 71.83M | 46.23M | 36.37M | 30.21M | 24.9M | 18.65M | 16.23M | 14.46M |
| OpEx % of Revenue | - | 2128.33% | 773.06% | 152.45% | 405.95% | 478.08% | 107.83% | 1043.14% | 1515.44% | 1125.94% | 826.1% | 1242.82% | - | 1920.29% | 607.75% | 1236.15% |
| Selling, General & Admin | 37.12M | 46.52M | 90.64M | 96.86M | 84.23M | 57.32M | 33.9M | 23.64M | 15.81M | 11.87M | 9.91M | 10.35M | 8.47M | 6.64M | 4.23M | 4.61M |
| SG&A % of Revenue | - | 699.99% | 664.95% | 152.45% | 87.47% | 102.64% | 107.83% | 221.32% | 333.5% | 289.16% | 225.19% | 425.83% | - | 683.73% | 158.35% | 393.59% |
| Research & Development | 95.81M | 107.83M | 135M | 172.6M | 320.45M | 215.52M | 125.62M | 87.77M | 56.02M | 34.36M | 26.45M | 19.86M | 16.43M | 12.01M | 12M | 9.86M |
| R&D % of Revenue | - | 1622.46% | 990.4% | 271.66% | 332.77% | 385.92% | 399.64% | 821.82% | 1181.94% | 836.78% | 600.91% | 816.99% | - | 1236.56% | 449.4% | 842.56% |
| Other Operating Expenses | -1000K | -12.9M | -120.26M | -172.6M | -13.76M | -5.85M | -125.62M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -131.1M | -147.7M | -210.28M | -190.51M | -308.39M | -216.99M | -128.09M | -100.73M | -67.09M | -42.13M | -31.96M | -27.78M | -24.9M | -17.68M | -13.56M | -13.29M |
| Operating Margin % | -2760.04% | -2222.45% | -1542.63% | -299.86% | -320.23% | -388.56% | -407.47% | -943.14% | -1415.44% | -1025.94% | -726.1% | -1142.82% | - | -1820.29% | -507.75% | -1136.15% |
| Operating Income Growth % | - | 29.76% | -10.37% | 38.22% | -42.12% | -69.41% | -27.16% | -50.13% | -59.27% | -31.79% | -15.05% | -11.56% | -40.9% | -30.38% | -1.99% | - |
| EBITDA | -119.66M | -138.41M | -191.31M | -172.23M | -294.63M | -211.14M | -125M | -98.53M | -65.89M | -41.15M | -31.08M | -27.09M | -24.41M | -17.1M | -12.97M | -12.62M |
| EBITDA Margin % | -2519.22% | -2082.59% | -1403.52% | -271.09% | -305.95% | -378.08% | -397.65% | -922.6% | -1390.04% | -1002.29% | -706.09% | -1114.56% | - | -1761.48% | -485.66% | -1078.72% |
| EBITDA Growth % | 25.25% | 27.65% | -11.08% | 41.54% | -39.54% | -68.92% | -26.86% | -49.55% | -60.1% | -32.4% | -14.71% | -11.01% | -42.7% | -31.9% | -2.74% | - |
| D&A (Non-Cash Add-back) | 11.44M | 9.29M | 18.96M | 18.28M | 13.76M | 5.85M | 3.09M | 2.19M | 1.2M | 971K | 881K | 687K | 496K | 571K | 590K | 672K |
| EBIT | -126.24M | -136.31M | -195.54M | -160.93M | -281.72M | -212.15M | -128.09M | -96.4M | -64.9M | -41.68M | -31.82M | -27.77M | -25.33M | -20.1M | -13.75M | -13.3M |
| Net Interest Income | 7.05M | 11.05M | 17.29M | 17.19M | 5.84M | 1.31M | 2.4M | 2.58M | 494K | -709K | -1.5M | -2.21M | -547K | -790K | -486K | -125K |
| Interest Income | 7.05M | 11.05M | 17.29M | 17.19M | 5.84M | 1.31M | 2.4M | 4.33M | 2.19M | 559K | 138K | 10K | 2K | 6K | 1K | 2K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.75M | 1.7M | 1.27M | 1.64M | 2.22M | 549K | 796K | 487K | 127K |
| Other Income/Expense | 6.67M | 11.39M | 24.01M | 29.58M | 26.66M | 4.84M | -45.3M | 2.58M | 494K | -827K | -1.5M | -2.21M | -979K | -3.22M | -682K | -134K |
| Pretax Income | -124.43M | -136.31M | -186.26M | -160.93M | -281.72M | -212.15M | -173.39M | -98.15M | -66.6M | -42.95M | -33.46M | -29.99M | -25.88M | -20.89M | -14.24M | -13.43M |
| Pretax Margin % | -2619.64% | -2051.08% | -1366.46% | -253.3% | -292.55% | -379.89% | -551.59% | -919% | -1405.02% | -1046.08% | -760.15% | -1233.73% | - | -2151.8% | -533.3% | -1147.61% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 297K | 0 | 0 | 53K | 0 | 0 | 127K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.69% | 0% | 0% | -0.2% | 0% | 0% | -0.95% |
| Net Income | -124.43M | -136.31M | -186.26M | -160.93M | -281.72M | -212.15M | -173.39M | -98.15M | -66.6M | -42.95M | -33.46M | -29.99M | -25.88M | -20.89M | -14.24M | -13.43M |
| Net Margin % | -2619.64% | -2051.08% | -1366.46% | -253.3% | -292.55% | -379.89% | -551.59% | -919% | -1405.02% | -1046.08% | -760.15% | -1233.73% | - | -2151.8% | -533.3% | -1147.61% |
| Net Income Growth % | 20.28% | 26.82% | -15.74% | 42.88% | -32.79% | -22.36% | -76.66% | -47.38% | -55.05% | -28.36% | -11.57% | -15.88% | -23.88% | -46.74% | -6.05% | - |
| Net Income (Continuing) | -124.43M | -136.31M | -186.26M | -160.93M | -281.72M | -212.15M | -173.39M | -98.15M | -66.6M | -42.95M | -33.46M | -29.99M | -25.88M | -20.89M | -14.24M | -13.43M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.01 | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 | -1.43 | -1.19 | -1.02 | -1.05 | -1.18 | -1.27 | -1.06 | -1.61 | -1.51 |
| EPS Growth % | 21.97% | 29.88% | 0% | 43.64% | -29.91% | -6.67% | -46.85% | -20.17% | -16.67% | 2.86% | 11.02% | 7.09% | -19.81% | 34.16% | -6.62% | - |
| EPS (Basic) | - | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 | -1.43 | -1.19 | -1.02 | -1.05 | -1.18 | -1.27 | -1.07 | -1.61 | -1.51 |
| Diluted Shares Outstanding | 123.66M | 118.79M | 113.69M | 98.41M | 96.83M | 94.75M | 82.39M | 68.19M | 56.2M | 41.98M | 31.75M | 25.48M | 20.45M | 19.75M | 8.87M | 8.87M |
| Basic Shares Outstanding | 123.66M | 118.79M | 113.69M | 98.41M | 96.83M | 94.75M | 82.39M | 68.19M | 56.2M | 41.98M | 31.75M | 25.48M | 20.45M | 19.44M | 8.87M | 8.87M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying FATE stock.
For fiscal year 2025, Fate Therapeutics, Inc. (FATE) reported total revenue of $6.6M. This represents a 468.0% increase compared to $1.2M in 2011.
Fate Therapeutics, Inc. (FATE) reported a net loss of $136.3M for the fiscal year ending 2025.
Fate Therapeutics, Inc. (FATE) reported an operating income of $-147.7M, resulting in an operating profit margin of -2222.4%. This margin reflects the operational efficiency of the business before interest and taxes.
Fate Therapeutics, Inc. (FATE) generated $-6.3M in gross profit for the year, representing a gross profit margin of -94.1%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Revenue sustainability amid losses
Metrics are mathematically derived from official filings.
Revenue Base Collapses Under Partnership Volatility
FATE's quarterly revenue has compressed from $6.8M in 2024Q2 to $2.1M in 2026Q2, a ~69% decline driven by lumpy collaboration milestones rather than product sales, rendering top-line trends unreliable indicators of underlying commercial traction according to the company's reported financials.
The revenue stream appears dominated by episodic collaboration or milestone payments rather than recurring product revenue, evidenced by wild swings such as the drop from $3.1M (2024Q3) to $1.7M (2025Q3) and the -96.7% YoY collapse in 2024Q1. This pattern suggests FATE lacks a commercialized product and remains dependent on partnership-triggered payments that may not be predictable or repeatable. Investors should question whether the modest 9.2% uptick in 2026Q2 reflects genuine pipeline momentum or simply a one-time recognition event.
Erratic Gross Margins Signal Misaligned Revenue Recognition
Gross margin oscillated between -124.6% (2026Q1) and 100% (2026Q2), reflecting that manufacturing and cost-of-goods expenses are not aligned with the timing of milestone-based revenue recognition, a structural distortion that makes margin analysis largely meaningless for FATE based on the reported data.
The negative gross profit in quarters like 2025Q3 (-$24.1M) versus the fully-absorbed 100% margins in 2026Q2 and 2025Q4 indicates that COGS — likely manufacturing scale-up and clinical material costs — are being incurred ahead of, or independent of, revenue recognition. This suggests significant operating infrastructure costs are being carried without corresponding commercial output. The company cannot claim meaningful pricing power or margin discipline until it generates product-based revenue where gross margins stabilize.
Aggressive Cost Cuts Narrow Losses Without Growth
R&D spending fell from $34.6M per quarter in 2024 to $24.4M in 2026Q2 (~30% reduction), while SG&A dropped from $31.7M to $8.8M (~72% reduction), cutting operating losses from -$61.7M to -$31.1M according to FATE's quarterly statements.
The bulk of the loss reduction comes from overhead and SG&A discipline rather than R&D retrenchment, suggesting the company protected pipeline investment while eliminating corporate infrastructure — a rational reallocation for a clinical-stage biotech. However, the simultaneous revenue decline means that cost cuts, not commercialization, are doing the heavy lifting on operating margin improvement. The trajectory from -$0.47 EPS (2024Q1) to -$0.25 (2026Q2) appears driven entirely by expense management, which has finite room to deliver further improvement.
SBC Wind-Down Masks Underlying Cash Consumption
Stock-based compensation declined from $11.0M in 2024Q1 to $3.5M in 2026Q2, a 68% reduction that flatters the trajectory of reported net losses, which improved from -$48.0M to -$30.2M over the same period per FATE's income statements.
SBC's contribution to operating expenses has fallen materially, which may indicate reduced equity issuance or reset option pricing rather than a structural shift in compensation philosophy — a distinction that matters for future dilution risk. Stripping out SBC, the underlying operating loss improvement is less dramatic, as a meaningful portion of the 'narrowing' reflects accounting normalization rather than operating efficiency gains. Tax rate and non-operating items show no anomalies, but net losses remain dominated by cash operating expenses, underscoring the gap between GAAP profitability and any near-term path to breakeven.
Cost Discipline Cannot Sustain a Biotech Without Revenue
FATE is burning ~$31M per quarter in operating losses against $2.1M in quarterly revenue (2026Q2), a 15:1 loss-to-revenue ratio that — absent a near-term regulatory or commercial catalyst — implies a finite runway that cost optimization alone cannot extend indefinitely.
The peer set includes companies like Intellia ($67.7M revenue) and Beam ($139.7M) that have materially larger collaboration or product revenue streams, highlighting FATE's relative commercial immaturity despite similar clinical-stage positioning. If the current revenue run-rate of ~$8M annualized persists while operating expenses stabilize at ~$125M/year, the implied cash consumption of $115M+ annually may force dilutive financing well before any product launch. Investors should scrutinize pipeline catalyst timing against remaining liquidity, as continued margin compression on an already negligible revenue base could accelerate the need for capital markets access.